Filing Flows

Filing Flows › 8-K events › Processa Pharmaceuticals

Processa Pharmaceuticals: departure or appointment of directors and officers

Form 8-K filed Nov 4, 2026 · items 5.02, 8.01

FDA decisionsProcessa Pharmaceuticals Announces Key Leadership Appointments

What the filing says

On November 2, 2026, the Board approved the appointment of Gregory J. Flesher as Chief Operating Officer of the Company, effective November 4, 2026 (the “ Start Date ”).

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Processa Pharmaceuticals’s other material 8-Ks

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.